Chat with Filing

Ask questions about this document
Please log in or register to use the chat feature. Please register first.
RNS - Faron-supported research in Theranostics identifies secreted Clever-1 (sClever-1) as an independent driver of immune evasion in cancer, deepening the understanding of bexmarilimab’s mode of action

Company: FARON PHARMACEUTICALS OY Date: 2025-06-30 Language: English Register to download
Loading document preview...
Document Preview Not Available

The file type (.html) cannot be displayed directly here.
Open Original File
Error loading document preview. Please try the 'Open Original File' link.
You're One Click Away From The Full Filing

Instantly access this document—and 2.8M more—for free. Select your preferred method:
Continue with Google Continue with Microsoft Continue with Facebook Continue with Amazon
 National Storage Mechanism | Additional information

Faron Pharmaceuticals

30 Jun 2025 06:00 UTC

- - -

# Faron-supported research in Theranostics identifies secreted Clever-1 (sClever-1) as an independent driver of immune evasion in cancer, deepening the understanding of bexmarilimab’s mode of action

Faron Pharmaceuticals Ltd | Press Release | June 30, 2025 at 09:00:00 EEST

***Study details how bexmarilimab treatment reduces circulating sClever-1 in patients with cancer, a key factor in T-cell suppression and PD-1 therapy resistance***

**TURKU, FINLAND** – Faron Pharmaceuticals Ltd. (AIM: FARN, First North: FARON), a clinical-stage biopharmaceutical company focused on tackling cancers through novel immunotherapies, announced the publication of a new study in the peer-reviewed journal *Theranostics*. The research identified a secreted, truncated form of the Clever-1 receptor (sClever-1) as a key immunosuppressive mediator in cancer that impaired T-cell responses and was associated with resistance to anti-programmed cell death protein -1 (PD-1) immunotherapies.

The study, supported by Faron Pharmaceuticals and grants from leading international funding bodies, including Cancer Research UK (CRUK), the NIHR Birmingham Biomedical Research Centre, the Research Council of Finland, and the Sigrid Jusélius Foundation, provided significant new insights into the biology of Clever-1, the target of Faron’s wholly owned, first-in-class immunotherapy asset, *bexmarilimab*. Clever-1 is an immunosuppressive receptor found on macrophages leading to tumor growth and metastases (i.e. helps cancer evade the immune system). 

In this study, researchers analyzed plasma samples from breast cancer patients (n=139) and *bexmarilimab*\-treated clinical trial participants (n=193) as well as healthy donors and discovered that a secreted form of Clever-1 or sClever-1 was significantly enriched in the plasma of cancer patients compared to healthy individuals.

“Our research unveils a previously unrecognized mechanism of immune suppression in cancer, where a secreted form of Clever-1 actively hinders T-cell responses,” said **Maija Hollmén, senior author of the study, MediCity Research Laboratory and InFLAMES Flagship, University of Turku, Turku, Finland.** “We have shown that sClever-1 operates independently of the cellular receptor and contributes to an immunosuppressive environment. This discovery not only deepens our understanding of cancer immunology but also strongly validates Clever-1 as a critical therapeutic target to overcome immune evasion.”

sClever-1, released by macrophages and endothelial cells, was found to bind to activated T cells, impairing their signaling and promoting the differentiation of suppressive T cells, contributing to tumor immune evasion. Moreover, high sClever-1 levels were associated with resistance to anti-PD-1 therapy.

Importantly, the study demonstrated that *bexmarilimab* treatment significantly reduced the release of sClever-1 in cancer patients. This reduction in circulating sClever-1 correlated with decreased engagement on T cells, providing a direct mechanistic link to the peripheral T-cell activation previously observed in *bexmarilimab*\-treated patients.  

The findings also suggest that high levels of sClever-1 are associated with resistance to anti-PD-1 checkpoint inhibitors, identifying sClever-1 as a potential biomarker to guide immunotherapy strategies. In patient-derived tumor explants, the addition of a recombinant sClever-1 protein led to a significant increase in the secretion of TGF-β, a key immunosuppressive cytokine.  

“These unique findings further solidify our conviction in *bexmarilimab's* unique mechanism of action,” **said** **Petri Bono, Faron’s Chief Medical Officer.** “The ability of *bexmarilimab* to reduce systemic levels of the immunosuppressive sClever-1 provides a clear rationale for its potential to overcome immunotherapy resistance. This adds to the growing body of evidence supporting *bexmarilimab’s* development as a potential cornerstone of immunotherapy for patients with aggressive cancers. This provides also a very intriguing basis of using soluble Clever-1 to inactivate T-cells in conditions where they are attacking our own body, i.e. in a wide range of auto-immune and inflammatory conditions”

Link to the original [article](https://www.thno.org/v15p7501.htm).

**For more information, please contact:**

|     |     |
| --- | --- |
| **IR Partners, Finland**  <br><br>**(Media)**  <br><br>Riina Tuominen  <br><br>Kare Laukkanen | +358 44 313 5005  <br><br>[riina.tuominen@irpartners.fi](mailto:riina.tuominen@irpartners.fi)  <br><br>+358 50 553 9535 / +44 7 469 766 223  <br><br>[kare.laukkanen@irpartners.fi](mailto:kare.laukkanen@irpartners.fi) |
| **FINN Partners, US**  <br><br>**(Media)**   <br><br>Alyssa Paldo | +1 847 791-8085   <br><br>[alyssa.paldo@finnpartners.com](mailto:alyssa.paldo@finnpartners.com) |
| **Cairn Financial Advisers LLP**  <br><br>**(Nominated Adviser and Broker)**  <br><br>Sandy Jamieson, Jo Turner | +44 (0) 207 213 0880 |
| **Sisu Partners Oy**  <br><br>**(Certified Adviser on Nasdaq First North)**  <br><br>Juha Karttunen  <br><br>Jukka Järvelä | +358 (0)40 555 4727  <br><br>+358 (0)50 553 8990 |

**About BEXMAB**  

The BEXMAB study is an open-label Phase I/II clinical trial investigating *bexmarilimab* in combination with standard of care (SoC) in the aggressive hematological malignancies of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). The primary objective is to determine the safety and tolerability of *bexmarilimab* in combination with SoC (azacitidine) treatment. Directly targeting Clever-1 could limit the replication capacity of cancer cells, increase antigen presentation, ignite an immune response, and allow current treatments to be more effective. Clever-1 is highly expressed in both AML and MDS and associated with therapy resistance, limited T cell activation and poor outcomes.

**About** ***bexmarilimab***  

*Bexmarilimab* is Faron’s wholly owned, investigational immunotherapy designed to overcome resistance to existing treatments and optimize clinical outcomes, by targeting myeloid cell function and igniting the immune system. *Bexmarilimab* binds to Clever-1, an immunosuppressive receptor found on macrophages leading to tumor growth and metastases (i.e. helps cancer evade the immune system). By targeting the Clever-1 receptor on macrophages, *bexmarilimab* alters the tumor microenvironment, reprogramming macrophages from an immunosuppressive (M2) state to an immunostimulatory (M1) one, upregulating interferon production and priming the immune system to attack tumors and sensitizing cancer cells to standard of care.

**About Faron Pharmaceuticals Ltd**  

Faron (AIM: FARN, First North: FARON) is a global, clinical-stage biopharmaceutical company, focused on tackling cancers via novel immunotherapies. Its mission is to bring the promise of immunotherapy to a broader population by uncovering novel ways to control and harness the power of the immune system. The Company’s lead asset is *bexmarilimab*, a novel anti-Clever-1 humanized antibody, with the potential to remove immunosuppression of cancers through reprogramming myeloid cell function. *Bexmarilimab* is being investigated in Phase I/II clinical trials as a potential therapy for patients with hematological cancers in combination with other standard treatments. Further information is available at [www.faron.com](http://www.faron.com/).

  

- - -

**MFN** is a regulatory news distribution service and it is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. The service is built to easily manage all the tasks of news distribution for listed companies.

For further information, please contact [support@modularfinance.com](mailto:support@modularfinance.com) or visit [Modular Finance](https://modularfinance.com/mfn).

View the source version on MFN: [Faron-supported research in Theranostics identifies secreted Clever-1 (sClever-1) as an independent driver of immune evasion in cancer, deepening the understanding of bexmarilimab’s mode of action](https://mfn.se/a/faron-pharmaceuticals/faron-supported-research-in-theranostics-identifies-secreted-clever-1-sclever-1-as-an-independent-driver-of-immune-evasion-in-cancer-deepening-the-understanding-of-bexmarilimabs-mode-of-action)